Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Foramsulfuron SCHEMBL19463617 | 0.87 | CDK1 (0.67) | CDK1KDM4ENPC1ALDH1A1GAA | |
| Foramsulfuron SCHEMBL116874 | 0.86 | CDK1 (1.00) | CDK1GAASMN1; SMN2 | |
| Foramsulfuron SCHEMBL29419146 | 0.86 | CDK1 (1.00) | CDK1GAASMN1; SMN2 | |
| Foramsulfuron SCHEMBL2320828 | 0.85 | CDK1 (0.98) | CDK1GAASMN1; SMN2 | |
| Foramsulfuron SCHEMBL2973354 | 0.85 | CDK1 (0.98) | CDK1ALDH1A1GAASMN1; SMN2HTT | |
| Foramsulfuron SCHEMBL15936497 | 0.84 | CDK1 (0.94) | CDK1GAASMN1; SMN2 | |
| SCHEMBL7060537 | 0.83 | CDK1 (0.90) | CDK1KDM4EALDH1A1GAASMN1; SMN2 | |
| Foramsulfuron SCHEMBL914629 | 0.82 | CDK1 (0.64) | CDK1GAA | |
| Foramsulfuron SCHEMBL19463680 | 0.82 | CDK1 (0.81) | CDK1KDM4ENPC1ALDH1A1GAA | |
| Foramsulfuron SCHEMBL19463951 | 0.81 | CDK1 (0.79) | CDK1KDM4EALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10448638-B2 | Synergistic weed control from applications of pyridine carboxylic acid herbicides and ALS inhibitors | DOW AGROSCIENCES LLC (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3193598-A1 | SYNERGISTIC WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND ALS INHIBITORS | Dow AgroSciences LLC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160135457-A1 | SYNERGISTIC WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND ALS INHIBITORS | DOW AGROSCIENCES | 2016-05-19 | — | — | US | disclosed |
| WO-2016044285-A1 | SYNERGISTIC WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND ALS INHIBITORS | DOW AGROSCIENCES LLC (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160135457-A1 | SYNERGISTIC WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND ALS INHIBITORS | NOTUM, ABAT, SOD1 | CDK1 2922/4885KDM4E 2442/4885NPC1 3727/4885 |
| US-10448638-B2 | Synergistic weed control from applications of pyridine carboxylic acid herbicides and ALS inhibitors | NOTUM, ABAT, SOD1 | CDK1 2922/4885KDM4E 2442/4885NPC1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.